Avadel Pharmaceuticals Plc Stock Today
| AVDL Stock | USD 8.10 0.14 1.70% |
PerformanceVery Weak
| Odds Of DistressLow
|
Avadel Pharmaceuticals is selling for 8.10 as of the 25th of February 2025. This is a 1.7 percent decrease since the beginning of the trading day. The stock's lowest day price was 7.97. Avadel Pharmaceuticals has less than a 9 % chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 27th of November 2024 and ending today, the 25th of February 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 7th of June 1996 | Category Healthcare | Classification Health Care |
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland. Avadel Pharmaceuticals is traded on NASDAQ Exchange in the United States. The company has 96.27 M outstanding shares of which 10.55 M shares are presently shorted by private and institutional investors with about 12.45 trading days to cover. More on Avadel Pharmaceuticals PLC
Moving together with Avadel Stock
Moving against Avadel Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Avadel Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| President | Gregory Divis | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Idea | Drugs (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, Drugs, Health Care, Pharmaceuticals, Drug Manufacturers—Specialty & Generic, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsAvadel Pharmaceuticals can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Avadel Pharmaceuticals' financial leverage. It provides some insight into what part of Avadel Pharmaceuticals' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Avadel Pharmaceuticals PLC (AVDL) is traded on NASDAQ Exchange in USA. It is located in 10 Earlsfort Terrace, Dublin, Ireland, 2 and employs 154 people. Avadel Pharmaceuticals is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.27 B. Avadel Pharmaceuticals conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 96.27 M outstanding shares of which 10.55 M shares are presently shorted by private and institutional investors with about 12.45 trading days to cover.
Avadel Pharmaceuticals PLC currently holds about 104.12 M in cash with (128.51 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.74.
Check Avadel Pharmaceuticals Probability Of Bankruptcy
Ownership AllocationAvadel Pharmaceuticals holds a total of 96.27 Million outstanding shares. The majority of Avadel Pharmaceuticals PLC outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Avadel Pharmaceuticals to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Avadel Pharmaceuticals. Please pay attention to any change in the institutional holdings of Avadel Pharmaceuticals PLC as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Avadel Ownership Details
Avadel Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Goldman Sachs Group Inc | 2024-12-31 | 2.1 M | |
| Tri Locum Partners Lp | 2024-12-31 | 1.9 M | |
| State Street Corp | 2024-12-31 | 1.7 M | |
| Ubs Group Ag | 2024-12-31 | 1.6 M | |
| Tang Capital Management Llc | 2024-12-31 | 1.5 M | |
| Millennium Management Llc | 2024-12-31 | 1.2 M | |
| Morgan Stanley - Brokerage Accounts | 2024-12-31 | 1.2 M | |
| Geode Capital Management, Llc | 2024-12-31 | 1.2 M | |
| Checkpoint Capital Lp | 2024-12-31 | 1 M | |
| Hhg Plc | 2024-12-31 | 14.1 M | |
| Gendell Jeffrey L | 2024-12-31 | 6.3 M |
Avadel Pharmaceuticals Historical Income Statement
Avadel Stock Against Markets
Avadel Pharmaceuticals Corporate Management
| Gregory Davis | VP Development | Profile | |
| Richard Kim | Chief Officer | Profile | |
| Christian PharmD | Chief Affairs | Profile | |
| Steven Sullivan | VP Operations | Profile | |
| Jason Vaughn | Senior Operations | Profile | |
| Jennifer PharmD | Senior Affairs | Profile |
Already Invested in Avadel Pharmaceuticals PLC?
The danger of trading Avadel Pharmaceuticals PLC is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Avadel Pharmaceuticals is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Avadel Pharmaceuticals. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Avadel Pharmaceuticals is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Avadel Pharmaceuticals is a strong investment it is important to analyze Avadel Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Avadel Pharmaceuticals' future performance. For an informed investment choice regarding Avadel Stock, refer to the following important reports: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Avadel Pharmaceuticals PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Avadel Pharmaceuticals. If investors know Avadel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Avadel Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.09) | Revenue Per Share | Quarterly Revenue Growth 26.743 | Return On Assets | Return On Equity |
The market value of Avadel Pharmaceuticals is measured differently than its book value, which is the value of Avadel that is recorded on the company's balance sheet. Investors also form their own opinion of Avadel Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Avadel Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Avadel Pharmaceuticals' market value can be influenced by many factors that don't directly affect Avadel Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Avadel Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Avadel Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Avadel Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.